CliffBio
small molecule

QUVIVIQ

DARIDOREXANT HYDROCHLORIDE

Loss of exclusivityDecember 2034latest FDA-listed patent expiry
CompanyIdorsia →View the full company profile on CliffBio

Drug detail

Brand nameQUVIVIQ
Active ingredientDARIDOREXANT HYDROCHLORIDE
StrengthEQ 50MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

Listed patents

PatentExpiresType
10023560December 2034use U-620
9790208December 2034substance, product
9732075June 2033substance, product

Regulatory exclusivity

CodeExpires
M-200September 2027
M-310September 2027
NCEApril 2027

More from Idorsia

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

QUVIVIQ patent cliff — loss of exclusivity December 2034 | CliffBio